Literature DB >> 17151146

The costs of drugs for schizophrenia.

Robert Freedman, William T Carpenter, John M Davis, Howard H Goldman, Carol A Tamminga, Marshall Thomas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17151146     DOI： 10.1176/ajp.2006.163.12.2029

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  4 in total

1.  Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment.

Authors:  Joseph Parks; Alan Radke; George Parker; May-Ellen Foti; Robert Eilers; Mary Diamond; Dale Svendsen; Rajiv Tandon
Journal:  Schizophr Bull       Date:  2008-04-02       Impact factor: 9.306

2.  What CATIE found: results from the schizophrenia trial.

Authors:  Marvin S Swartz; T Scott Stroup; Joseph P McEvoy; Sonia M Davis; Robert A Rosenheck; Richard S E Keefe; John K Hsiao; Jeffrey A Lieberman
Journal:  Psychiatr Serv       Date:  2008-05       Impact factor: 3.084

Review 3.  Randomized controlled trials for schizophrenia: study designs targeted to distinct goals.

Authors:  T Scott Stroup; John R Geddes
Journal:  Schizophr Bull       Date:  2008-01-31       Impact factor: 9.306

4.  Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia.

Authors:  Robert Rosenheck; Haiqun Lin
Journal:  J Nerv Ment Dis       Date:  2014-01       Impact factor: 2.254
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.